Core Viewpoint - The approval of clinical trials for human coagulation factor IX by the National Medical Products Administration marks a significant advancement in the research and development of blood products for the company, targeting treatment for patients with hemophilia B [1] Company Summary - The company, Huaren Boya Biological Pharmaceutical Group Co., Ltd., has received approval for clinical trials of human coagulation factor IX, specifically for treating bleeding in patients with coagulation factor IX deficiency (hemophilia B) [1] - The total research and development investment for this project has reached approximately RMB 16.32 million [1] - The company aims to expand into high-value niche markets, providing more treatment options for domestic hemophilia B patients [1] Industry Summary - The current market for similar products includes competitors such as Shandong Taibang Biological Products Co., Ltd. and Yuanda Shuyang Life Sciences (Chengdu) Co., Ltd., indicating a competitive landscape [1] - Hemophilia B is classified as a rare disease, with a strong and rigid demand for medication among patients, alongside a clear need for domestic alternatives [1]
博雅生物获得人凝血因子Ⅸ药物临床试验批准